A phase II trial aiming to investigate the safety and clinical activity of belantamab mafodotin in adult patients with primary immune thrombocytopenia previously treated with a thrombopoietin receptor agonist and/or rituximab after corticosteroid first-line therapy - BONSAI
EAE140
Phase 2 other active
Quick answer
A phase II trial aiming to investigate the safety and clinical activity of belantamab mafodotin in adult patients with primary immune thrombocytopenia previously treated with a thrombopoietin receptor agonist and/or rituximab after corticosteroid first-line therapy - BONSAI for Primary Immune Thrombocytopenia is a Phase 2 program (other) at Ology Bioservices Ireland LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ology Bioservices Ireland LTD
- Indication
- Primary Immune Thrombocytopenia
- Phase
- Phase 2
- Modality
- other
- Status
- active